Rhythm Pharmaceuticals, Inc. · NASDAQ:RYTM
Rhythm Pharmaceuticals — Q3 2026 Earnings Presentation
29 slides from Rhythm Pharmaceuticals's earnings presentation, Nov 3, 2026
Slide 1: Third Quarter 2026 Financial Results and Business Update
Rhythm Pharmaceuticals Third Quarter 2026 Financial Results and Business Update November 3, 2026 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved.
Slide 2: On Today's Call
On Today’s Call • David Connolly, Vice President of Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Jennifer Lee, Executive Vice President, Head of North America • Yann Mazabraud, Executive Vice President, Head of International • Hun
Slide 3: Forward-looking Statements
Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be
Slide 4: David Meeker, MD
David Meeker, MD Chair, President and CEO ® 4
Slide 5: Q3 2026: Executing Today, Building for Tomorrow
Q3 2026: Executing Today, Building for Tomorrow Business Highlights Strong aHO launch progress drives revenue growth Japan aHO launch underway, expanding global commercial footprint MC4R portfolio royalty reduced to 1% under amended bivamelagon licensing agreement Bivamelagon to advance to Phase 3 t
Slide 6: MC4R Agonism Development Across Three Pillars
MC4R Agonism Development Across Three Pillars Next-generation MC4R agonists Genetic MC4R Pathway Diseases RM-718 Bivamelagon (weekly injection) (daily oral) Hypothalamic Obesity Global commercial foundation Prader-Willi Syndrome established by IMCIVREE in BBS ® 6
Slide 7: Bivamelagon Advancing into Two Pivotal Trials
Bivamelagon Advancing into Two Pivotal Trials Acquired hypothalamic obesity • Global, phase 3 placebo-controlled trial • 52 weeks • Primary endpoint: BMI reduction Prader-Willi syndrome 100 mg 200 mg 400 mg 600 mg • Global, phase 3 placebo-controlled trial • 26 weeks • Primary endpoint: Hyperphagia
Slide 8: Jennifer Lee
Jennifer Lee EVP, Head of North America ® 8
Slide 9: Strong Momentum in Second Quarter of U.S. Launch in Acquired HO
Strong Momentum in Second Quarter of U.S. Launch in Acquired HO Strong patient Broadening Favorable demand prescriber access and continues base coverage ® 9
Slide 10: Strong Patient Demand and Early Uptake
Strong Patient Demand and Early Uptake Start Forms Patients by age Hypothalamic injury ~20% >700 4-11yo ~15% Patient Start Forms within two years ~50% >22yo Inclusive of 71 start forms from ~30% ~35% clinical trial patients 12-21yo >10 years Note: Between FDA approval on March 19, 2026 and Septembe
Slide 11: Following Patient Journey Beyond the First Point of Contact
Following Patient Journey Beyond the First Point of Contact ~500 incident patients begin their journey ~30% each year at major medical centers of patients remain or large healthcare organizations at original point of care ~70% of patients referred or transitioned outside the original point of care F
Slide 12: Specialty Opportunity with Broadening Prescriber Base
Specialty Opportunity with Broadening Prescriber Base Prescribers Specialty >500 80% Unique prescribers Endocrinologists evenly split among ~25% adult and pediatric providers Repeat aHO Prescribers Note: Between FDA approval on March 19, 2026 and September 30, 2026. ® 12
Slide 13: Progress in Time to Approval and Expanding Patient Access
Progress in Time to Approval and Expanding Patient Access Reimbursement Approvals Payers Positive Policies Secured 75% of approvals at or 2/3 of approvals occur 60% of Medicaid covered lives without prior auth in less than 60 days 75% of commercial covered lives Note: Between FDA approval on March 1
Slide 14: Continued Strength in BBS Business
Continued Strength in BBS Business Patient Growth Field Force Continued growth in Dedicated BBS patients on therapy field force ® 14
Slide 15: Yann Mazabraud
Yann Mazabraud EVP, Head of International ® 15
Slide 16: IMCIVREE Now Commercially Available for aHO in Japan
IMCIVREE Now Commercially Available for aHO in Japan 5,000 – 8,000 estimated patients with acquired HO in Japan1 Commercial launch initiated October 13, 2026 1. Rhythm estimates the prevalence of acquired hypothalamic obesity in Japan to be approximately 5,000 to 8,000 based on our review of tumor r
Slide 17: Disease Awareness Increasing through Education and Engagement
Disease Awareness Increasing through Education and Engagement Guidelines for the Diagnosis and Treatment of Acquired HO Published by the Japanese Endocrine Society & MHLW-funded Research Group Joint Statement on the Safe and Appropriate Use of Setmelanotide Acetate Injection for Acquired Hypothalami
Slide 18: Experienced Rare Disease Team in Place to Support Japan Launch
Experienced Rare Disease Team in Place to Support Japan Launch An Experienced Team in Place >50 16 6 Rhythm Employees Hospital Affairs Scientific Affairs in Japan Leads Managers Targeting Strategy ~350 Priority hospitals ® 18
Slide 19: Physician Engagement, Patient Identification Provide Strong Starting Point
Physician Engagement, Patient Identification Provide Strong Starting Point Field teams already have engaged with…. … and identified…. ~300 Out of 350 priority hospitals >1,000 where brain tumors patients likely are treated eligible for IMCIVREE ® 19
Slide 20: IMCIVREE HO Country-level Launches Expected in 2027
IMCIVREE HO Country-level Launches Expected in 2027 • Germany G-BA process ~10,000 initiated estimated European prevalence1 • Reimbursement dossiers submitted: • France • Italy • UK • Spain • The Netherlands 1. European estimates limited to the EU4 (Germany, France, Spain, Italy), UK and the Netherl
Slide 21: Hunter Smith
Hunter Smith Chief Financial Officer ® 21
Slide 22: Rhythm, LG Chem Amend Bivamelagon Exclusive License Agreement
Rhythm, LG Chem Amend Bivamelagon Exclusive License Agreement Royalty on MC4R Portfolio Sales Low-to-mid-single digits → 1% Beginning Jan. 1, 2029, or first commercial sale of bivamelagon, if earlier Original Agreement Amendment Cash paid / payable $80M upfront $350M additional paid over four years*
Slide 23: $750M Term Loan Facility Secured
$750M Term Loan Facility Secured $750M Total Facility SOFR + 4.60% 5-year term 1.0% OID $250M $250M Initial draw Optional tranches 1.00% SOFR floor No amortization Original issue discount through June 30, 2028 $250M Favorable amendments to 2022 Rhythm and HCRx additional capacity subject to mutual l
Slide 24: Well-capitalized Following Recent Financing
Well-capitalized Following Recent Financing Cash on-hand does not include: $320.9M +$250M Initial draw under Term Loan Facility cash, cash equivalents and short- term investments as of Paid within 15 business days September 30, 2026 following the effective date of the -$70M bivamelagon Exclusive Lic
Slide 25: Q3 2026: Meaningful Growth in IMCIVREE Global Sales
Q3 2026: Meaningful Growth in IMCIVREE Global Sales QoQ increase $92.1M 29% from Q2 2026 20% increase in number of Net Product Revenue 73% of Q3 2026 revenue from U.S. patients globally on reimbursed therapy ® 25
Slide 26: Q2 '26 to Q3 '26: Strong Commercial Growth Driven by U.S. HO Launch
Q2 ‘26 to Q3 ‘26: Strong Commercial Growth Driven by U.S. HO Launch $15.1M $4.4M $92.1M $71.3M $1.3M Ex-US revenue increase of $600K U.S. Q2-Q3 U.S. revenue Q2 2026 inventory effect at change from and Q2 Q3 2026 Product $3.8M charge due Product specialty pharmacy product dispensed revenue to French
Slide 27: Q3 2026 Financial Snapshot
Q3 2026 Financial Snapshot ($ in millions, except per share Three months ended Three months ended data and shares outstanding) September 30, 2026 September 30, 2025 Product revenue, net $92.1M $51.3M R&D expenses $52.5M $46.0M SG&A expenses $66.8M $52.4M Net Loss attributable to common stockholders
Slide 28: Q3 2026 Financial Highlights and Guidance
Q3 2026 Financial Highlights and Guidance Q3’ 2026 OpEx 2026 OpEx Guidance $119.2M $360M to $380M Q3 2026 OpEx anticipated non-GAAP Operating includes Expenses* for 2026 includes: $25.0M in stock-based R&D: $165M to $175M compensation expense SG&A: $195M to $205M * Non-GAAP Operating Expenses is a n
Slide 29: Questions
Questions Rhythm
Rhythm Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix